Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707486 | 1.00 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL29505702 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL18765302 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL5010733 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Formaldehyde SCHEMBL28853991 | 0.94 | UHRF1 (0.47) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL11616480 | 0.82 | UHRF1 (0.46) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL2750563 | 0.80 | UHRF1 (0.45) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL554353 | 0.80 | NOS3 (0.70) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL19413769 | 0.80 | UHRF1 (0.45) | UHRF1NOS3NOS1NOS2SLC6A4 | |
| SCHEMBL28198255 | 0.80 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528908-A | Antitumor compound, preparation method, pharmaceutical composition containing compound and application of compound | 承德医学院 | 2025-02-28 | — | — | CN | claimed |
| CN-118745144-A | Novel EZH2 inhibitor compound, and preparation method and application thereof | 辽宁大学 | 2024-10-08 | — | — | CN | claimed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | claimed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | claimed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | claimed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | claimed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | claimed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-3950682-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| WO-2025076501-A1 | HIGH THROUGHPUT PARALLEL SYNTHESIS OF SMALL MOLECULE DEGRADERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-118745144-A | Novel EZH2 inhibitor compound, and preparation method and application thereof | 辽宁大学 | 2024-10-08 | — | — | CN | disclosed |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| CN-113330008-B | Preparation method of amide compound and application of amide compound in medicine field | 上海华汇拓医药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-3704089-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023061467-A1 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | 江苏恒瑞医药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20230104823-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CYCLACEL LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| WO-2022258023-A1 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3452453-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022008426-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| WO-2021148793-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CYCLACEL LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3704089-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| CN-110041250-A | The benzene compound being substituted | EPIZYME股份有限公司 | 2019-07-23 | — | — | CN | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
| CN-105017221-B | Benzimidizole derivatives and its preparation method and pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2019-05-28 | — | — | CN | disclosed |
| CN-109790160-A | Pyrido 5-membered aromatic cyclics, preparation method and the usage | 上海海和药物研究开发有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-3452453-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-109320499-A | Pyrrole-3-carboxamide class compound and its preparation method and application | 沈阳药科大学 | 2019-02-12 | — | — | CN | disclosed |
| CN-105102432-B | Substituted Benzene Compounds | EPIZYME股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2018138500-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| CN-108314677-A | A kind of novel EZH2 inhibitor and application thereof | 中国科学院合肥物质科学研究院 | 2018-07-24 | — | — | CN | disclosed |
| CN-105308038-B | The inhibitor of Zeste enhancers homologue 2 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-105102446-B | Conditioning agent, its composition and the purposes of methyl modification enzyme | 星座制药公司 | 2018-01-23 | — | — | CN | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| CN-107311921-A | Aryl or heteroaryl-substituted compound | EPIZYME股份有限公司 | 2017-11-03 | — | — | CN | disclosed |
| CN-107148419-A | The inhibitor of ZESTE enhancers homologue 2 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-104066718-B | Substituted benzene compounds | EPIZYME股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-104080769-B | Aryl or heteroaryl substituted benzene compounds | EPIZYME股份有限公司 | 2017-06-20 | — | — | CN | disclosed |
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| US-9173938-B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2011131135-A1 | HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 北京大学 (CN) | 2011-10-27 | — | — | WO | disclosed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-20100143350-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139486-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | UHRF1 1228/4885NOS3 1413/4885NOS1 1279/4885 |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | UHRF1 4809/4885NOS3 3992/4885NOS1 2927/4885 |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | UHRF1 3811/4885NOS3 2210/4885NOS1 1847/4885 |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | UHRF1 3811/4885NOS3 2210/4885NOS1 1847/4885 |
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | EZH2, IKZF2, EZH1 | UHRF1 60/4885NOS3 1365/4885NOS1 1078/4885 |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | UHRF1 4755/4885NOS3 2755/4885NOS1 1382/4885 |
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | UHRF1 2824/4885NOS3 2705/4885NOS1 3258/4885 |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | UHRF1 1228/4885NOS3 1413/4885NOS1 1279/4885 |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | UHRF1 3649/4885NOS3 2233/4885NOS1 2469/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | UHRF1 1228/4885NOS3 1413/4885NOS1 1279/4885 |
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | UHRF1 3733/4885NOS3 1380/4885NOS1 918/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | UHRF1 3776/4885NOS3 2174/4885NOS1 2101/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | UHRF1 4809/4885NOS3 3992/4885NOS1 2927/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | UHRF1 3776/4885NOS3 2174/4885NOS1 2101/4885 |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | UHRF1 1228/4885NOS3 1413/4885NOS1 1279/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | UHRF1 4680/4885NOS3 2959/4885NOS1 4311/4885 |
| US-20100143350-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK4, CDK2, CDK3 | UHRF1 2517/4885NOS3 3895/4885NOS1 4249/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | UHRF1 3814/4885NOS3 1960/4885NOS1 1539/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | UHRF1 4858/4885NOS3 4317/4885NOS1 4347/4885 |
| US-20230104823-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CDK9, CDK19, CDK7 | UHRF1 1169/4885NOS3 2997/4885NOS1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.